Comprehensive medication guide to Tiagabine including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay for generic tiagabine on most Medicare Part D and commercial insurance plans (Tier 2–3); prior authorization may be required if step therapy applies.
Estimated Cash Pricing
$385–$432 retail for generic tiagabine (30-day supply); as low as $45 with GoodRx Gold or $152 for 60 tablets with SingleCare at participating pharmacies.
Medfinder Findability Score
78/100
Summarize with AI
On this page
Tiagabine (brand name Gabitril) is an FDA-approved anticonvulsant medication used to help control partial (focal) seizures in adults and children 12 years and older with epilepsy. It was first approved by the FDA in 1997 and is available as both brand-name and generic tablets.
Tiagabine is always used as adjunctive therapy — in combination with other antiepileptic drugs — rather than as a standalone medication. It is a second- or third-line option typically prescribed when partial seizures are not adequately controlled by first-line AEDs such as levetiracetam or lamotrigine.
The drug is available in oral tablet form in 2mg, 4mg, 12mg, and 16mg strengths and is taken 2-4 times daily with food. Tiagabine is not a controlled substance under federal DEA scheduling.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Tiagabine works through a unique mechanism among anticonvulsants: it selectively inhibits GABA transporter-1 (GAT-1), the protein responsible for removing GABA (gamma-aminobutyric acid) from the synapse after it is released. GABA is the brain's primary inhibitory neurotransmitter — the chemical that tells neurons to calm down and stop firing.
By blocking GAT-1, tiagabine prevents the rapid clearance of GABA from the synapse. This allows GABA to remain active longer, binding to inhibitory receptors on neighboring neurons and prolonging the inhibitory post-synaptic potential. The result is enhanced inhibitory signaling in the brain — specifically in the cortex and hippocampus where partial seizures often originate — making it harder for abnormal electrical activity to start or spread.
This mechanism is distinct from virtually all other antiepileptic drugs, which primarily work by blocking sodium or calcium channels, or by directly modulating GABA receptors. Tiagabine's unique approach makes it a useful option for patients who have not responded to AEDs with other mechanisms.
2 mg — tablet
Low starting dose for titration
4 mg — tablet
Most common starting and maintenance dose
12 mg — tablet
Higher-dose maintenance tablet
16 mg — tablet
Higher-dose maintenance, used in enzyme-induced patients
Tiagabine is not in a formal FDA shortage as of 2026. However, because it is a niche adjunctive antiepileptic drug prescribed to a relatively small patient population, many retail pharmacies do not routinely stock it. Patients frequently report that their local pharmacy doesn't carry their specific strength, requiring a special order or a trip to a different pharmacy.
The findability score for tiagabine is 78/100 — it's generally available through the wholesale supply chain, but not always on the shelf at your nearest pharmacy. Mail-order pharmacies and large wholesale-connected pharmacies are the most reliable sources. If you're having trouble locating tiagabine near you, medfinder can call pharmacies near you to find which ones have your specific medication in stock.
Tiagabine is not a controlled substance, so there are no special DEA registration requirements beyond standard prescribing authority. Any licensed physician, nurse practitioner, or physician assistant with full prescribing authority can prescribe tiagabine. In practice, however, it is almost exclusively prescribed and managed by specialists due to its complexity.
Neurologists — Primary prescribers; manage most adult epilepsy patients on tiagabine
Epileptologists — Subspecialists in epilepsy; most likely to prescribe tiagabine as a second- or third-line adjunctive AED
Pediatric neurologists — For patients aged 12-17 years
Nurse practitioners and physician assistants — With neurology training; often manage ongoing refills for stable epilepsy patients
Primary care physicians — May manage refills for stabilized patients; rarely initiate tiagabine
Telehealth is available for follow-up and refill management of stable tiagabine patients, though initial epilepsy evaluation typically requires in-person assessment including EEG and neuroimaging. Platforms like Neura Health and major health system telehealth portals offer neurology video visits for established patients.
No. Tiagabine (Gabitril) is not a controlled substance under federal DEA scheduling in the United States. It is classified as a prescription-only medication, but it does not carry any of the special DEA requirements — such as specific prescription formats, quantity limits, or refill restrictions — that apply to Schedule II-V controlled substances.
This means tiagabine can be prescribed by any licensed prescriber (physicians, NPs, PAs) with standard prescribing authority, can be called in by phone or sent electronically, and can be filled with refills up to what is permitted on the prescription. It can also be prescribed via telehealth without the restrictions that apply to Schedule II substances.
Despite not being controlled, tiagabine is a serious medication that should only be used as prescribed. Abrupt discontinuation can trigger severe seizures, and off-label use has been associated with new-onset seizures. Always use tiagabine exactly as directed by your neurologist.
Most tiagabine side effects are dose-related and tend to be most noticeable during the initial titration phase. Common side effects include:
Dizziness (most common)
Drowsiness / somnolence
Asthenia (weakness or fatigue)
Nervousness
Memory impairment
Tremor
Headache
Diarrhea
Depression and emotional lability
New or worsening seizures (including status epilepticus)
Suicidal thoughts or behavior
Stevens-Johnson syndrome (severe skin rash with fever)
Severe or incapacitating generalized weakness
Visual changes or color perception disturbances
Know what you need? Skip the search.
Lamotrigine (Lamictal)
Broad-spectrum AED; widely available generic; requires slow titration to prevent rash
Levetiracetam (Keppra)
First-line adjunctive AED; minimal drug interactions; widely available and inexpensive generic
Oxcarbazepine (Trileptal)
Approved for monotherapy and adjunctive use; watch for hyponatremia and oral contraceptive interaction
Topiramate (Topamax)
Multiple mechanisms; also approved for migraine prevention; cognitive side effects and kidney stone risk
Lacosamide (Vimpat)
Newer AED for partial onset seizures; Schedule V; monitor for cardiac conduction effects
Prefer Tiagabine? We can find it.
Carbamazepine (Tegretol)
majorEnzyme-inducing AED; reduces tiagabine levels by 50-75%; requires higher tiagabine doses
Phenytoin (Dilantin)
majorPotent enzyme inducer; significantly reduces tiagabine plasma levels; requires dose adjustment
Phenobarbital
majorMajor enzyme inducer; reduces tiagabine blood levels; tiagabine dose must be adjusted
Alcohol
majorSignificantly worsens CNS depression (dizziness, drowsiness, impaired coordination) caused by tiagabine
Valproate (Depakote)
moderateDisplaces tiagabine from plasma proteins, increasing free drug fraction; monitor for toxicity
Benzodiazepines
moderateAdditive CNS depression with tiagabine; combination increases sedation and impairment
St. John's Wort
moderateCYP3A4 inducer; reduces tiagabine blood levels similar to enzyme-inducing AEDs
Ketoconazole
moderateCYP3A4 inhibitor; may increase tiagabine blood levels; dose reduction may be needed
Opioid analgesics
moderateAdditive CNS and respiratory depression; use combination with caution
Primidone (Mysoline)
majorEnzyme inducer (partially metabolized to phenobarbital); reduces tiagabine levels
Tiagabine (Gabitril) is a useful adjunctive anticonvulsant for patients with partial seizures who have not achieved adequate control with first-line medications. Its unique GAT-1 inhibition mechanism offers a different approach to seizure control and has been proven effective when used appropriately as part of a comprehensive epilepsy management plan.
The key challenges with tiagabine are its complex dosing (highly dependent on concomitant AEDs), potential for significant drug interactions, and the clinical seriousness of dose interruptions. Patients should never stop tiagabine abruptly and should plan refills proactively to ensure continuous supply. Retail prices can be high, but significant savings are available through GoodRx and insurance coverage of the generic formulation.
If you're having trouble filling your tiagabine prescription at your local pharmacy, medfinder can help you find pharmacies near you that have it in stock — without spending your afternoon on the phone.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini